# UC Davis Dermatology Online Journal

## Title

Beta blocker treatment for infantile hemangiomas

## Permalink

https://escholarship.org/uc/item/05k4t1hq

## Journal

Dermatology Online Journal, 21(7)

## **Authors**

Rouhana, Hailey Frances Fruge, Jill Huckabee Massengale, William Trent

## **Publication Date**

2015

**DOI** 10.5070/D3217028111

## **Copyright Information**

Copyright 2015 by the author(s). This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</a>

Peer reviewed

## Volume 21 Number 7 July 2015

Review

Beta blocker treatment for infantile hemangiomas

Hailey Frances Rouhana MD, Jill Huckabee Fruge MD, William Trent Massengale MD

Dermatology Online Journal 21 (7): 2

### Louisiana State University School of Medicine

### **Correspondence:**

Hailey Frances Rouhana Louisiana State University School of Medicine hrouhana@gmail.com

## Abstract

Infantile hemangiomas (IH) are common childhood vascular tumors. Treatment of IH has undergone rapid change in recent years. Since 2008, oral propranolol has been used to treat complicated IH and has proven superior to previously used therapies. More recently, the efficacy of other systemic beta blockers, specifically atenolol and nadolol, has been reported. In addition, topical timolol solution has been effective for treatment of smaller, more superficial IH. The purpose of this article is to review the current literature of beta-blocker therapy for IH.

### Keywords: Beta blocker, propranolol, atenolol, nadolol, timolol, infantile hemangioma

## Introduction

Infantile hemangiomas (IH) are the most common benign vascular tumors in children, with an incidence of 4-10% in infants [1, 2]. The natural course of IH is rapid proliferation during the first few weeks or months of life, followed by a plateau period, and then involution over several years [3]. Most involute spontaneously without treatment; 90% of IH completely regress by 9 years of age [4]. However, approximately 10% of IH require intervention to prevent or treat complications such as functional impairment, disfigurement, scarring, and painful ulceration [5].

Traditionally, oral corticosteroids were the treatment of choice despite varied efficacy and frequent, serious adverse events [3]. Preferred first-line therapy quickly shifted after the 2008 publication by Léauté-Labrèze *et al.* describing the dramatic effect of oral propranolol on IH involution discovered while treating two children with high output cardiac failure [6]. Since then, many articles have reported favorable results with propranolol in IH. Propranolol was found to be safer, more tolerable, and more effective than previously used corticosteroids. However, propranolol does have risks and serious potential adverse effects include hypotension, bradycardia, hypoglycemia, and bronchospasm. The mechanism of beta-blocker therapy for IH is not fully understood. Rapid vasoconstriction, inhibition of angiogenesis, induction of apoptosis, and decreased renin production may play a role [3].

Propranolol is a lipophilic non-selective beta blocker that crosses the blood brain barrier. The beta-adrenergic system plays a role in memory modulation and novelty detection; the potentially harmful long-term effects of beta-blocking agents on the central nervous system (CNS) in infancy are unknown [7]. More recently, atenolol and nadolol have been studied as alternative systemic beta blockers for treatment of IH. These drugs do not cross the blood brain barrier, theoretically eliminating the potential risk of CNS effects, such as sleep disturbance and future memory deficits. Compared to propranolol, less frequent dosing is required for atenolol (once daily) and nadolol (twice daily), which may increase patient compliance [7, 8, 9].

Atenolol is a hydrophilic cardioselective beta blocker that acts primarily as a  $\beta$  1-receptor antagonist and spares  $\beta$  2-receptors. Therefore, bronchospasm and hypoglycemia associated with  $\beta$  2 blockade are essentially negated with atenolol [8, 9]. Nadolol is a hydrophilic non-selective beta blocker. In contrast to propranolol, nadolol has less myocardial depressant activity and a longer half-life (12-24 hours), which decreases rebound growth [7]. The topical  $\beta$  -blocker timolol is an alternative to oral propranolol for smaller, more superficial IH to reduce the risks of adverse events associated with systemic therapy [10, 11, 12]. The purpose of this article is to review the current literature of beta-blocker therapy for IH.

# Methods

In October 2014, four PubMed searches were performed using the terms ['Infantile hemangioma'] AND ['propranolol'], ['atenolol'], ['nadolol'], or ['timolol']. Propranolol and timolol searches were limited to clinical trials or randomized controlled trials. In addition, three propranolol articles included in this review were PubMed related citations.

Articles written in Chinese were excluded. The authors of articles that could not be accessed were contacted; those that did not respond were excluded from this review.

Study design, year(s) the study was conducted or year of publication, duration of therapy, number of patients treated with beta blocker, mean age at treatment initiation, IH location and type, beta blocker dose, divided daily dose or frequency, outcome/efficacy, adverse events, and number of patients with rebound/regrowth after treatment completion were recorded for each study. Not all variables were reported in every study.

# RESULTS

### A. Oral propranolol

Twenty-two articles describing the efficacy of propranolol in the treatment of infantile hemangiomas were included in this review (Table 1) [8,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33]. Despite a lack of uniformity or standardization with measured outcomes, several observations including dose, overall response, response time, and rebound occurrence can be made. The most commonly used propranolol dose was 2 mg/kg/day divided TID; although many variations have been reported from 0.75-4 mg/kg/day divided BID-TID. Overall, mean age of patients treated during the proliferative phase was 5 months. Six studies reported treatment of IH after the proliferative phase ranging from 11-31 months of age.

Overall, 15 studies reported a 100% response rate to oral propranolol. Of the studies that did not report a 100% response rate, non-responders ranged from 3-10%. There appears to be an association between age at treatment and IH response, with Sondhi et al. reporting 100% response in patients less than 6 months, 89% response in patients aged 6-36 months, and 0% response in patients older than 36 months [19]. Additionally, Fuchsmann et al. cited the two treatment failures occurring in patients with delayed treatment [31]. Response time was not reported in all studies, but several studies report softening and lightening of color within 24-48 hours [13, 16, 17, 21]. Holmes et al. reported 100% cessation of proliferation at 2 weeks with regression in 55% of IH during that same period [23]. Similarly, Léauté-Labrèze et al. reported 100% cessation of proliferation after 1 month of treatment [13]. Furthermore, Zvulunov et al. showed that addition of propranolol during IH involution in patients with a mean age of 28 months led to increased involution rates [33].

Mean duration of therapy ranged from 1-14 months, with an average of 7 months. Interestingly, Sondhi et al. reported that treatment after 20 weeks duration was associated with no further significant response [19]. Rebound or recurrence was seen in 13 studies with rates ranging from 2.5% to 40%. Overall, the majority of rebounds was characterized as re-coloration and mild regrowth and was reported to be successfully retreated with oral propranolol. Three studies reported zero recurrence or rebound [16, 19, 22]. Ma et al. associated recurrence with early discontinuation of propranolol after only 4-5 months [20].

Ulcerated hemangiomas were specifically reported on by 6 authors. Several publications cited healing of ulcerations anywhere from 2 weeks to 2 months [17, 21, 27, 31]. Manunza et al. reported rapid resolution in small ulcerations compared to limited resolution in larger ulcerations [30]. Additionally, Hermans et al. noted that 70% of patients with an ulcerated IH treated after 3.5 months of age had ulcer duration beyond 8.7 weeks of treatment [28]. Furthermore, Saint-Jean et al. commented that ulcerated hemangiomas on the head and neck resolved faster than those located elsewhere. Only Saint-Jean et al. reported recurrence of ulceration during rebound. However, they noted resolution of ulceration with re-administration of oral propranolol [27].

Study	Study design	Year	Duration	# of	Age*	IH location	Dose	Divided	Outcome/Efficacy	Adverse events	Rebound/Regrowth
			of therapy	treated		& type	(mg/kg/d)	daily			
Léauté- Labrèze et al.	Monocenteric double- blinded randomized placebo- controlled trial	2008-2010	1 mo	6	3 mos	Various locations	3 for 15 days and then 4 for 15 additional days	N/A	Within 1 month, IH growth stopped and significant involution ensued in all propranolol-treated patients. In the propranolol group, IH thickness decreased by a mean of 45% (compared to a mean increase of 11% in the placebo group), and IH size decreased by a mean of 16% (compared to a mean increase of 9% in the placebo group). Within 24 hrs of propranolol initiation, softening and color change from intense red to purple was noted, with continued improvement throughout treatment.	Drowsiness (1), asymptomatic mild decrease in heart rate and diastolic blood pressure	N/A
Hogeling et al.	Double- blinded, randomized placebo- controlled parallel- group trial	2009-2010	6 mos	19	17 mos	Various, mostly facial	2	3	60% decrease in tumor volume (compared to 14% in the placebo group). In the propranolol group, IH growth stopped by week 4, and there was a significant decrease in redness and elevation at weeks 12 and 24 compared to the placebo group. A significant difference in percent change in volume between the groups was found at all weeks, with the largest difference at week 12.	Upper respiratory tract infection (1), bronchiolitis (4), viral gastroenteritis (1), streptococcal infection (1), cool extremities (1), dental caries (1), sleep disturbance (2)	Not formally assessed, but mild rebound redness and growth was seen.
Bauman et al.	Multi- institutional investigator -blinded randomized placebo- controlled trial	2010-2012	11 mcs*	9	3 mos	Various	2	3	64% decrease in the mean total surface area at 4 mos of treatment	Dehydration (1), asymptomatic hypoglycemia after the first dose only (1). Some patients had asymptomatic BP decreases that resolved spontaneously, and there was an	22% (2/9)
										increased incidence of upper respiratory tract infections	
Malik et al.	Randomized controlled trial	2011- 2012	10 mcs*	10	5 mos	Various, mostly head and neck and superficial	2*	2	According to geometric measurements, maximum reduction occurred in the propranolol group in the first 3 mos with a mean reduction of 36 $\pm$ 21%. All IH's continued to decrease in size at 6, 12 and 18 mos. Mean size reduction (%) $\pm$ SD based on VAS: At 3 mos: 58 $\pm$ 20 At 6 mos: 71 $\pm$ 18 At 12 mos: 85 $\pm$ 11 At 18 mos: 90 $\pm$ 10 Mean initial response time	Asymptomatic hypoglycemia at the start of treatment (1), somnolence (1)	None
									was 4 $\pm$ 3 days. There was significant early IH flattening, change in consistency within 24 hrs, and color fading within 48 hrs. All IH's continued to fade in color compared to baseline.		
Abarzúa- Araya et al.	Double- blinded randomized controlled trial	2012-2013	6 mos	10	5 mos	Various	2	3	60% complete response (complete resolution; residual telangiectasia and redundant tissue were considered complete response); 40% partial response (any improvement in size, color, or consistency that did not meet complete response criteria)	None	40% (4/10); all responded to reintroduction of propranolol
Sans et al.	Prospective clinical study	Publish ed in 2009	6 mos*	32	4 mos for early interven tion (27 pts); 31 mos for late interven tion (5 pts)	Various	2-3	2 or 3	Propranolol efficacy was 100%. In all IHs, softening and color change from intense red to purple was observed within 24 hrs, with continued Improvement thereafter. Ulcerations completely healed in <2 mos. In the 11 patients who had ultrasound exams, results showed 40% mean regression	wheezing/Asthma onset (1), Blood pressure decrease 3 hrs after first dose that resolved spontaneously (1), Insomnia (2), Agitation (2), Nightmares (1), Profuse sweats (1).	4/16 mild recoloration 3/16 mild regrowth; 2 patients restarted treatment with good results

Section     Comparison											in maximal thickness and a	Cold hands (1)	
Cent     Cent <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>27% increase in mean resistivity index indicating</td><td></td><td></td></th<>											27% increase in mean resistivity index indicating		
Vertikel bit attal     Progenetike Lange     Sold Sold bit     Sold Bit     Sold Bit     <											lower vascular activity within		
Vertex     circle     213     Imp     0     Classes     p	$\left  \right $	Managilla	Decementing	2000	Const	<u></u>	Creating As	Marlaur	2*	2	the IH.	Nege	1 month often
Shuff   Shuff <th< td=""><td></td><td>o et al.</td><td>clinical</td><td>2008-</td><td>6 mos.</td><td>00</td><td>&lt;12 mos</td><td>various</td><td>2</td><td>5</td><td>propranolol was successful in</td><td>None</td><td>discontinuation:</td></th<>		o et al.	clinical	2008-	6 mos.	00	<12 mos	various	2	5	propranolol was successful in	None	discontinuation:
Souther al.     Souther concerned states     Souther concerned st			study				(mean				stopping proliferation and		recoloration or mild
Section     Section <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>7 mos)</td><td></td><td></td><td></td><td>accelerating involution of IHs.</td><td></td><td>regrowth in 24%</td></t<>							7 mos)				accelerating involution of IHs.		regrowth in 24%
Sechiet Souther Single James							[se brs]				decreased redness and		severe regrowth in
Sendire     Sender     South and the sender sender the sender the sender sender the sender the sender sender sender sender the sender sen							Group B:				palpable softening was noted		15% (10/68)
South Ite     Single- unit     2001: 2011     Single- set     2011: 2011							>12 mos				within a few days of starting		
Security of the second secon							(mean 19 mos)				was observed in many cases		
And Intervention     Standard     Barry Standard     Barry Standard     Market Barry Standard							[32 pts]				after 1-2 weeks of		
Link     Link <thlink< th="">     Link     Link     <thl< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>propranolol. Continued</td><td></td><td></td></thl<></thlink<>											propranolol. Continued		
Security 1   Security 1 <td></td> <td>some hemangiomas</td> <td></td> <td></td>											some hemangiomas		
Souff et al. Single al. 2000 bits 8 mm <sup>2</sup> 31 11 mot south and south and so											becoming nearly flat in 6-8		
South Int Space <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>weeks.</td><td></td><td></td></td<>											weeks.		
Self-ter Single- self-ter 200- self-ter 8 mm <sup>2</sup> 11 mm Various 2 2 2 20/12 (Single- model-term) Incomise (2), self-term branched met model-term bran											patients had marked		
Mart II Properties 2001 8 mot* 3.3 11 mos Various 2 2 2001/0000000000000000000000000000000000											improvement after the first		
Image: Source of the second											month.		
Southiet     Single- center, teaching al.     2009. 2011     8 mos*     31     11 mos     Various     2     2     2013 (1000 patients) showed patients thread patients in the 300 to center, teaching pace showed patients in the 300 to center, teaching pace showed patients in the 300 to center, teaching pace showed patients in the 300 to center, teaching patients in the 300 teaching patient in the 3											(91%) patients had marked		
Image: Second Pieter Single- int Control     Sound Pieter Single- control     Sound Pieter Single- control     Sound Pieter Single- control     None at the 6 month second paper mode.     More at the 6 month second paper mode.       Soudd Pieter Single- controller und Vieter Pieter Single- controller Und     8 mox*     3 1     11 mos     Various     2     2     24/04 (0%) proper mode. Sound Pieter Single- controller paper section     More at the 6 month second paper mode.     More at the 6 month second paper mode.     More at the 6 month second paper mode.       Image: Single- control     2011     8 mox*     3 1     11 mos     Various     2     24/04 (0%) unreaded paper mode.     Image: Single- control     More at the 6 month second manual patients (Single- tion)     Image: Single- sound paper mode.     More at the 6 month second manual patients (Single- gift on the compared with noutreamout paper mode.     Single- paper mode.     More at the 6 month second manual patients (Single- gift on the compared with mode paper mode.     Single- paper mode.     More at the 6 month second manual patients (Single- gift on the compared with mode paper mode.     Single- paper mode.     More at the 6 month second manual patients (Single- gift on the compared with mode paper mode.     Single- paper mode. <td></td> <td>and moderate improvement</td> <td></td> <td></td>											and moderate improvement		
Soudh'set al.     Single- carter.     2005.     8 mos*     51     11 mos     Various     2     2     2     2     2     2     3     1500 mail total reads particular transfer particular properiod variant particular partion particular particular partion particular partic											respectively after the first		
Image: Source in all in the source in all intervention of a set of the source intervention of a set of the source intervention in the control of the source intervention is source intervention intervention of the source intervention is source intervention of the source intervention of the source intervention intervention of the source intervention of the source intervention of the source intervention is source intervention intervention intervention of the source intervention is source intervention interventint inter											no improvement.		
Sondhirt et al. Single- statistically controlled general-ale 2000 2011 8 mm* 31 11 mms Various 2 2 2 2 2/30 [0W] represented and source to general the control group. Four another statistically gate in the control group. Four another statistically gate in the control group. Four another statistical program (b). None at the 6 month follow-up statistical four-spectra statistical program (b).   Me et al. Progescher, 2011 2 <td></td> <td>Propranolol was ineffective in</td> <td></td> <td></td>											Propranolol was ineffective in		
Mater     Test     Solutional propositional productin productional productin productio	$\left  \right $	Sondh! et	Single	2000	8 mor*	31	11 mer	Variour	2	2	7% of patients.	Insomple (2)	None at the 6 month
Initiationality constrained propertive generative generat		al.	center,	2009-	o mos*	21	11 mos	various	2	2	treated patients had >50%	bronchospasm (1)	follow-up visit
controlled proposed/weight   controlled (spen-habel Unial   controlled bill   controlled (spen-habel Unial   controled (spen-habel Unial   control			historically-								involution of IH, compared to		
Cellet   Progenities   2011   14 mox*   28 mox*   14 mox*   24 mox*   14 mox*			controlled								only 4/14 (29%) untreated		
Liui			open-label								Propranolol-treated patients		
Me et al.   Prospective   2019   14 most   67   7 mos   Variaus   2.7   2   Specifically spectrates and gradues of the resolution of the resolutis resolution of the resolution of the resol			trial								demonstrated significantly		
Me et al. Prospective, 2009: 14 mos* 69 4 mos Various 0 0.75-1 2 During the fixt week, in reported of the step of portandol was statistically ingerticant, but the state step of the step of portandol was statistically with 6-00 Action of the step of portandol was statistically ingerticant, but the state of the step of portandol was statistically ingerticant and server the state step of portandol was statistically ingerticant. Mid diarrie that state step of portandol: 30/20 (100%) potents - 5 mos of personal was not propared with water of program of the state step of portandol: 30/20 (100%) potents - 5 mos of personal was not propared with water of personal was statistically with 6-00 Action during this firm. From 5 to 20 weeks, in restauration in H was also not program of was statistically might cart. Mid diarrhea that state was also not program of was statistically might cart. Mid diarrhea that state was also not program of was statistically might cart. Mid diarrhea that state was also not program of was statistically might cart. Mid diarrhea that state was also not program of was statistically might cart. Mid diarrhea that state was also not program of was statistically might cart. Mid diarrhea that state was also not program of was statistically might cart. Mid diarrhea that state was also not program of was statistically might cart. Mid diarrhea that state was also not program of was statistically might cart. Mid diarrhea that state was also not program of was statistically might cart. Mid diarrhea that state was also not program of was statistically might cart. Mid diarrhea that state was also not program of was states the program of the state was also not program of the state was ala case. Mid diarrhea that state was also not program											faster and greater degree of		
Ma et al. Prospective, series 200- 2011 14 mos* 89 (Chinese) 4 mos Various various 0.75-1 2 Durates of proparability displications Mild during the first series Mild during the first series   Ma et al. Prospective series 200- 2011 14 mos* 89 (Chinese) 4 mos 0.75-1 2 Durates first series Mild during the first series 4.5% (4/98), all of whom discontinued series   Cellit et elliptical 14 mos* 89 (Chinese) 4 mos Various 0.75-1 2 During the first wesk series 4.5% (4/98), all of whom discontinued series 4.5% (4/98), all of whom discontinued ser											no treatment.		
Ma et al.     Prospective, 2009- intervention     14 mox*     89 (a)     4 mox     0.75-1     2     During and motion (a), segments     Mid diarrhea that (b), segments     4.5% (4/89), all of whom discontinued programmed in sectors       Ma et al.     Prospective, 2009- intervention     14 mox*     89     4 mox     Various     0.75-1     2     During and programmed in sectors     4.5% (4/89), all of whom discontinued programmed in sectors       Ma et al.     Prospective, 2009- intervention programmed in sectors     14 mox*     89 (B)     4 mox     Various programmed in sectors     0.75-1     2     During the first week, programmed in sectors     4.5% (4/89), all of whom discontinued programmed in sectors       Cell et al.     programmed in sectors     programmed in sectors     4.5% (4/89), all of whom discontinued programmed in sectors     4.5% (4/89), all of whom discontinued programmed in sectors <td></td> <td>The overall mean score for</td> <td></td> <td></td>											The overall mean score for		
Image: Construct of the service of the serv											(4.4) was significantly better		
Let <td></td> <td>than untreated patients (8.4).</td> <td></td> <td></td>											than untreated patients (8.4).		
Ma et al.     Prospective active series     2009- 2011     14 mos*     89 89     4 mos     Various Various     0.75-1     2     During the first series     Mild diarrhea that reduction in the solution during this time. From 8 to 20 weeks, statistically significant reduction in the solution during this time. From 8 to 20 weeks, statistically significant reduction in the solution during this time. From 8 to 20 weeks, statistically significant reduction in the solution during this time. From 8 to 20 weeks, statistically significant reduction in the solution during this time. From 8 to 20 weeks, statistically significant reduction in the solution during this time. From 8 to 20 weeks, statistically significant reduction in the solution during this time. From 8 to 20 weeks, statistically significant reduction in the solution during this time. From 8 to 20 weeks, statistically significant reduction in the solution during this time. From 8 to 20 weeks, statistically significant reduction in the solution solution during this time. From 8 to 20 weeks, statistically significant reduction in the solution reduction the solution solution during the first solution during the first solutis during the first solutis during the first solution	l										3 patients (10%) did not		
Ma et al.   Prospective, 2011   214 mox*   89   4 mox   Various   0.75-1   2   Decrease in size and redness was most processed to the difference of	ſ										improve with propranolol		
Ma et al.   Prospective, 2011   200*   34 mos*   89   4 mos   Various   0.75-1   2   Culting the first week, with 65-30% of involution during this time. From 8 to 20 weeks, statistically applications to programoid values asserties   Mild diarrhea that segments and means the program of the first weeks, with 65-30% of involution during this time. From 8 to 20 weeks, statistically applications the program of the molume of the first weeks, with 65-30% of involution during this time. From 8 to 20 weeks, statistically applications the program of the molume of the first weeks, with 65-30% of involution during the first week, statistically applications the program of the molume of the first weeks, with 65-30% of involution during the first week is statistically applications that generative is a series   4.5% (4/89), all of whom discontinued program of the first weeks, with 65-30% of involution during the first week is spontaneously by the end of the first week is spontaneously by the end of the first week is spontaneously by the end of the first week is spontaneously by the end of the first week is spontaneously by the end of the first week is end (1), susse (2), and (1), susse (2)											despite 12 wks of therapy.		
Ma et al.   Prospective.   2001   14 mos*   89   4 mos   Various   0.75-1   2   201/2 Oxologiations 5 is mos											Response to Propranolol:		
Ma et al.   Prospective, 2011   14 mos*   89   4 mos   Various   0.75-1   2   During the fragment to the soft or gare on the soft or gare gare on the soft or gare on the soft or gare on the s											20/20 (100%) patients ≤ 6		
Ma et al.   Prospective, intervention al case series   2009- 10 arms   14 mcs*   89 (Chinese)   4 mcs   Various locations   0.75-1   2   20 uetas, response to progranoid was   Mild darrhea that resultability lightly statistically inglificant resolved statistically inglificant   Mild darrhea that resolved statistically inglificant   4.556 (4/89), all of whom discontinued progranoid was     Ma et al.   Prospective, al case   2009- series   14 mcs*   89 (Chinese)   4 mcs   Various locations   0.75-1   2   During first week, with resolved progranoid was   Mild darrhea that resolved spontaneously by whom discontinued progranoid treatment afcr 4-5 months.   4.556 (4/89), all of whom discontinued progranoid treatment afcr 4-5 months.     Ma et al.   Prospective, as refers   2009- as erises   14 mcs*   89 (Chinese)   4 mcs   Various locations   0.75-1   2   Using first week, week (3), respective regression was noted in parts of the Hs.   Mild darrhea that resolved spontaneously by who discontinued resolved spontaneously by the read of the first week (3), resiles sing first hoge, spontaneously by the resolved spontaneously by the resolved spontaneously by the resolved spontaneously color treatment affr 4-5 months: 44/89 (50%) patients had good response (0-75%) regression) 24/89 (24%) patients had good response (0-75%) regression)   4.556 (4/89), all of the Hist   4.556 (4/89), all of the Hist     Celiit t   Prospective   2009- at											mos of age		
Ma et al.   Prospective, intervention   2009-   14 mcs*   89   4 mcs   Various   0.75-1   2   20 weeks, statistication in the sales on noted in parts of the inst.   Mild diarrheat that resolved in the sales on noted in parts of the inst.   4.556 (4/89), all of weeks, statistication in the sales on noted in parts of the inst.   4.556 (4/89), all of weeks, statistication in the sales on noted in parts of the inst.   4.556 (4/89), all of weeks, statistication in the sales on noted in parts of the inst.   4.556 (4/89), all of weeks, statistication in the week is statistication in the sales on noted in parts of the inst.   4.556 (4/89), all of weeks, statistication in the week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is states of the week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the first week is statisticated by the end of the lits.   4.556 (4/89), all of th											of age		
Ma et al.   Prospective, series   200-   14 mcs*   89   4 mcs   Various   0.75-1   2   Decrease in size and redness, was most pronounced in the first 3 weeks, with 65-50% of revolution during this time. From 8 to 200 weeks, restatically significant reduction in IH was also noted. Beyond 20 weeks, restatically insignificant statically insignificant.   Mild diarrhea that superficial leaves during the first week, s											0/2 (0%) patients > 36 mos		
Ma et al. Prospective, al case series 200- 2011 14 mos* 89 (Chinese) 4 mos Various locations 0.75-1 2 20 Mid diarrhea that reduction in H was also noted. Beyrong 20 weeks, response to programolol was statistically significant reduction in H was also noted. Beyrong 20 weeks, response to programolol was statistically significant Mid diarrhea that resolved sponse to programolol was statistically significant 4.5% (4/69), all of who discontinued programolol was statistically significant   Ma et al. Prospective, al case 2001- al case 14 mos* 89 (Chinese) 4 mos Various locations 0.75-1 2 During the first week, superficial lesions changed or purple, and subcutaneous lesions changed in texture (soft). Mid diarrhea that resolved or purple, and subcutaneous lesions changed in texture (soft). 4.5% (4/69), all of who discontinued programolo treatment after 4-5 months.   After 3 months; complete regression al. 2001- al. 14 mos* 69 (Chinese) 4 mos Various 0.75-1 2 2011 Mid diarrhea that subcutaneous lesions changed in texture (soft). 4.5% (4/69), all of who discontinued programolo treatment after 4-5 months.   After 3 months; complete regression 21/89 (27%) patients had fair regression) 2012 21/89 (24%) patients had fair regression) 21/89 (24%) patients had fair regression) 21/89 (24%) patients had poor regression) 21/89 (24%) patients had poor regression)   Cellitet Prospective 200- al.											Decrease in size and redness		
Image: Section of the section of t											was most pronounced in the		
Ma et al. Prospective, 2009- al case series 2011 14 mcs* 89 (Chinese) 4 mcs Various iscations 0.75-1 2 During the first week, response to progranold was statistically lightficant. Mild diarrhea that prospective, 2011 44 mcs* 89 (Chinese) 4 mcs Various iscations 0.75-1 2 During the first week, subscript and to medium. Mild diarrhea that progranold treatment afcr 4-5 months. 4.5% (4/89), all of whom discontinued progranold treatment afcr 4-5 months.   Ma et al. Prospective, series 2011 14 mcs* 89 (Chinese) 4 mcs Various iscations 0.75-1 2 During the first week, subscript and to medium. Mild diarrhea that progranold treatment after 4-5 months. 4.5% (4/89), all of whom discontinued progranold treatment after 4-5 months.   Make bar bar bar bar bar bar progranold treatment after 4-5 months. After 5 months: After 6 mo											first 8 weeks, with 65-80% of		
Ma et al. Prospective, 2009- intervention al case series 2009- 2011 14 mos* 89 (Chinese) 4 mos Various (Chinese) 0.75-1 2 During the first week, supericial lesions changed color from intense-red tored or purple, and subcutaneous lesions changed in texture series Mild diarrhea that sportaneously by the end of the first series 4.5% (4/89), all of whom discontinued progranold treatment after 4–5 months.   Ma et al. Prospective, accesseries 2009- 2011 14 mos* 89 (Chinese) 4 mos Various locations 0.75-1 2 During the first week, supericial lesions changed color from intense-red to red or purple, and subcutaneous lesions. Changed in texture from hard to medium. After 3 months, supericial lesions, complete regression was noted in parts of the His. Mild diarrhea that sportaneously by the end of the first selep (1), nausea (2), charter 4–5 months. 4.5% (4/89), all of whom discontinued progranold treatment after 4–5 months.   Various 2 After 6 months; after 4–5 months 4.5% (4/89), all of whom discontinued progranole treatment of the His. Mild diarrhea that sportaneously by the end of the first regression was noted in parts of the His. 4.5% (4/89), all of whom discontinued progranole (3.1), regression all of the His. 4.5% (4/89), all of whom discontinued progranole (3.1), regression (2.1), all of the His. 4.5% (4/89), all of whom discontinued progranole (3.1), regression (2.1), all of the His. 4.5% (4/89), all of whom discontinued progranole (3.1), regression (2.1), all of the His. 4.5% (4/89), all of whom discontinued progranole (3.1), regression (2.1), all o											involution during this time. From 8 to 20 weeks.		
Ma et al.   Prospective, intervention al case series   2009- 2011   14 mcs*   89 (Chinese)   4 mcs   Various locations   0.75-1   2   Duming the first week, statistically insignificant.   Mild diarrhea that resolved color from interse-red to red or purple, and subcutaneous lesions changed in texture from mard to medium. After 3 months, most IHs improvement in color (purple, with areas of gray) and texture (soft).   Mild diarrhea that week (8), restless spontaneous) by the end of the first week (8), restless and the first spontaneous) by the end of the first week (8), restless and the first spontaneous) by the end of the first week (8), restless and the first spontaneous) by the end of the first spontaneous) b											statistically significant		
Ma et al. Prospective, intervention al case series 2009- total model 14 mcs* 89 (Chinese) 4 mcs Various (Chinese) 0.75-1 2 During the first week, superficial lesions changed color from intense-red to red from hard to medium. After 3 months, most IHs regressed with further (d), slight levelated ALT and AST (5) 4.5% (4/89), all of whom discontinued propranolol treatment after 4-5 months.   Cellk et el Prospective (linical 2009- 2011 14 mcs* 89 (Chinese) 4 mcs Various locations 0.75-1 2 During the first week, superficial lesions changed color from intense-red to red from hard to medium. After 3 months, most IHs regression was noted in parts of the IHs. Mild diarrhea that superficial lesions changed (d), slight levelated ALT and AST (5) 4.5% (4/89), all of whom discontinued propranolol treatment after 4-5 months.   Cellk et el Prospective el 2009- 2011 8 mos* 67 7 mos Various 2 2 Within 24 hrs of propranol 0/89 (0%) patients had poor response (26-50% regression) 0/89 (0%) patients had poor response (26-50% regression) None 2 wks after stopping propranol											reduction in IH was also		
Ma et al.   Prospective, intervention al case series   2009- intervention 2011   14 mos*   89 (Chinese)   4 mos   Various void solutions   0.75-1   2   During the first week, superficial lesions changed color from intense-red to red or purple, and subcutaneous lesions changed in texture from hard to medium. After 3 months, most His regressed with further improvement in color (purple with areas of gray) and texture (soft).   Mild diarrhea that resolved spontaneously by the end of the first week (8), restless slep (1), nausea (2), cold externities (1), slight hypoglycemia (4), slightly elevated ALT and AST (5)     Cellk et al.   Prospective al.   2009- 2011   8 mos*   67   7 mos   Various   2   2   Within 24 hs of propranolol response (0-25% regression) 0/89 (0%) patients had poor response (0-25% regression)   None   2 wks after stopping torgranolod 10											response to propranolol was		
Ma et al.   Prospective, intervention al case series   2001   14 mcs*   89   4 mcs   Various locations   0.75-1   2   During the first week, superficial lesions changed color from intense-red to red or purple, and subcutaneous lesions changed in texture sige [1), nause [2], respective, [4], sight hypoglycemia after 4–5 months.   Mild diarrhae that travele (3), restless signature (1), respective (4), sight hypoglycemia after 4–5 months.   Mond discontinued programolol treatment after 4–5 months.     Ma et al.   Prospective, intervention al case   2011   14 mcs*   89   (Chinese)   4 mcs   Various   0.75-1   2   During the first week, superficial lesions changed in texture superficial lesions changed in texture (4), sight hypoglycemia after 4–5 months.   Mond discontinued programolol treatment after 4–5 months.     After 3 months, most IHs regression was noted in parts of the IHs.   After 6 months:   Add sight elevated ALT and AST (5)   After 6 months:   Add sight elevated excellent response (76-100% regression)   Ald sight global conditions and excellent response (76-100% regression)   21/39 (23%) patients had good response (25-57% regression)   24/39 (27%) patients had fair response (26-50% regression)   None   2 wks after stopping programed 10     Celik et   Prospective al clinical   2001-   8 mos*   67   7 mcs   Various   2   2   Within 24 hrs of propranolo   None											statistically insignificant.		
Intervention   ZOLL   Commession   Continues   Indications   Superical lesions changed color from intense-red to red or purple, and subcutaneous lesions changed in texture from hard to medium. After 3 months, most IHs regressed with further improvement in color (purple, with areas of gray) and texture (soft). After 6 months: of the IHs.   Pesoleed programmed treatment after 4–5 months.   Whom discontinued programoid treatment after 4–5 months.     After 3 months   After 3 months   After 3 months: may area of gray) and texture (soft). After 6 months: of the IHs.   After 6 months: After 8 months: After	ſ	Ma et al.	Prospective,	2009-	14 mos*	89 (Chinasa)	4 mos	Various	0.75-1	2	During the first week,	Mild diarrhea that	4.5% (4/89), all of
series   series   series   or purple, and subcutaneous lesions changed in texture from hard to medium. After 3 months, most Hs regressed with further improvement in color (purple with areas of gray) and texture (soft). After 6 months: 4ALT and AST (5)   after 4–5 months. after 4–5 months.     All and AST (5)   After 3 months, most Hs regression was noted in parts of the IHs.   After 6 months: 4ALT and AST (5)   All and AST (5)     Celik et al.   Prospective 2009- 2011   2009- 2011   8 mos*   67   7 mos   Various   2   2   Within 24 hrs of proprenoid initiation all nationation   None   2 wks after stopping prospecided 10			al case	2011		(cninese)		ocations			color from intense-red to red	spontaneously by	propranolol treatment
Celik et   Prospective   2009-   8 mos*   67   7 mos   Various   2   2   Within 24 hrs of progranold   None   2 wks after stopping			series								or purple, and subcutaneous	the end of the first	after 4–5 months.
Celik et   Prospective   2009-   8 mos*   67   7 mos   Various   2   2   Within 24 hrs of progranolol   None   2 wks after stopping     Celik et   Prospective   2009-   8 mos*   67   7 mos   2 arises   2   2   Within 24 hrs of progranolol   None   2 wks after stopping											lesions changed in texture	week (3), restless	
Celik etProspective2009- 20118 mos*677 mosVarious22Within 24 hrs of propriatesNone2 wks after stopping regressionCelik etProspective2009- 20118 mos*677 mosVarious22Within 24 hrs of propriatesNone2 wks after stopping regression											After 3 months, most IHs	cold extremities (1).	
Celik etProspective2009- al.8 mos*677 mosVarious22Warious22Within 24 hrs of progranoidNone2 wks after stopping10											regressed with further	slight hypoglycemia	
Celik et   Prospective   2009-   8 mos*   67   7 mos   Various   2   2   Within a fair of progranolol   None   2 wks after stopping     al.   clinical   2019-   8 mos*   67   7 mos   Various   2   2   Within a fair of progranolol   None   2 wks after stopping											improvement in color (purple		
Celik et   Prospective   2009-   8 mos*   67   7 mos   Various   2   2   Within 24 hrs of propranolol   None   2 wks after stopping     al.   clinical   2011-   10   10   10   10											with areas of grav) and	(4), slightly elevated	
Celik et   Prospective   2009-   8 mos*   67   7 mos   Various   2   2   Within 24 hrs of progranolol   None   2 wks after stopping     10   clinical   2011   2011   10   10   10											with areas of gray) and texture (soft).	(4), slightly elevated ALT and AST (5)	
Celik et   Prospective   2009-   8 mos*   67   7 mos   Various   2   2   Within 24 hrs of progranolol   None   2 wks after stopping     1   clinical   2011   2011   7 mos   Various   2   2   Within 24 hrs of progranolol   None   2 wks after stopping											with areas of gray) and texture (soft). After 6 months, complete	(4), slightly elevated ALT and AST (5)	
Celik et   Prospective   2009-   8 mos*   67   7 mos   Various   2   2   Within 24 hrs of progranolol   None   2 wks after stopping     al.   clinical   2011   2011   7 mos   Various   2   2   Within 24 hrs of progranolol   None   2 wks after stopping											with areas of gray) and texture (soft). After 6 months, complete regression was noted in parts of the IHs.	(4), slightly elevated ALT and AST (5)	
Celik et   Prospective   2009-   8 mos*   67   7 mos   Various   2   2   Within 24 hrs of progranolol   None   2 wks after stopping     al.   clinical   2011   2011   10   10											with a reas of gray) and texture (soft). After 6 months, complete regression was noted in parts of the IHs.	(4), slightly elevated ALT and AST (5)	
Celik et Prospective 2009- 8 mos* 67 7 mos Various 2 2 Within 24 hrs of progranolol None 2 wks after stopping   al. clinical 2011 2011 10											with a reas of gray) and texture (soft). After 6 months, complete regression was noted in parts of the IHs. After 6 months:	(4), slightly elevated ALT and AST (5)	
Celik et Prospective 2009- 8 mos* 67 7 mos Various 2 2 Within 24 hrs of propranolol None 2 wks after stopping   al. clinical 2011 2011 Celik et Prospective 2009- 8 mos* 67 7 mos Various 2 2 Within 24 hrs of propranolol None 2 wks after stopping											with a reas of gray) and texture (soft). After 6 months, complete regression was noted in parts of the IHs. After 6 months: 44/89 (50%) patients had excellent response (76-100%)	(4), slightly elevated ALT and AST (5)	
Celik et Prospective 2009- 8 mos* 67 7 mos Various 2 2 Within 24 hrs of propranolol None 2 wks after stopping   al. clinical 2011 2011 0 0 0 0 0											with a reas of gray) and texture (soft). After 6 months, complete regression was noted in parts of the IHs. After 6 months: 44/89 (50%) patients had excellent response (76-100% regression)	(4), slightly elevated ALT and AST (5)	
Celik et Prospective 2009- 8 mos* 67 7 mos Various 2 2 Within 24 hrs of propranolol None 2 wks after stopping   al. clinical 2011 2011 Celik et Prospective 2009- 8 mos* 67 7 mos Various 2 2 Within 24 hrs of propranolol None 2 wks after stopping											with a reas of gray) and texture (soft). After 6 months, complete regression was noted in parts of the IHs. After 6 months: 44/89 (50%) patients had excellent response (76-100% regression) 21/89 (24%) patients had end response (51-75%	(4), slightly elevated ALT and AST (5)	
Celik et Prospective 2009- 8 mos* 67 7 mos Various 2 2 Within 24 hrs of propranolol None 2 wks after stopping   al. clinical 2011 2011 0 0 0 0 0 0											Min provenient in toxic (pulpie with a reas of gray) and texture (soft). After 6 months, complete regression was noted in parts of the IHs. After 6 months: 44/89 (50%) patients had excellent response (76-100% regression) 21/89 (24%) patients had good response (51-75% regression)	(4), slightly elevated ALT and AST (5)	
Celik et     Prospective     2009-     8 mos*     67     7 mos     Various     2     2     Within 24 hrs of propranolol     None     2 wks after stopping       al.     clinical     2011     0     10     0 <td></td> <td>with a reas of gray) and texture (soft). After 6 months, complete regression was noted in parts of the IHs. After 6 months: 44/89 (50%) patients had excellent response (76-100% regression) 21/89 (24%) patients had good response (51-75% regression) 24/89 (27%) patients had fair</td> <td>(4), slightly elevated ALT and AST (5)</td> <td></td>											with a reas of gray) and texture (soft). After 6 months, complete regression was noted in parts of the IHs. After 6 months: 44/89 (50%) patients had excellent response (76-100% regression) 21/89 (24%) patients had good response (51-75% regression) 24/89 (27%) patients had fair	(4), slightly elevated ALT and AST (5)	
Celik et     Prospective     2009-     8 mos*     67     7 mos     Various     2     2     Within 24 hrs of propranolol     None     2 wks after stopping       al.     clinical     2011     2     Various     2     2     Within 24 hrs of propranolol     None     2 wks after stopping											with areas of gray) and texture (soft). After 6 months, complete regression was noted in parts of the IHs. After 6 months: 44/83 (50%) patients had excellent response (76-100% regression) 21/89 (24%) patients had good response (51-75% regression) 24/89 (27%) patients had fair response (26-50% regression) 0/89 (0%) patients had poor	(4), slightly elevated ALT and AST (5)	
i i i i i i i i i i i i i i i i i i i											Min provenient in toticity (pulpie with a reas of gray) and texture (soft). After 6 months, complete regression was noted in parts of the IHs. After 6 months: 44/89 (50%) patients had excellent response (76-100% regression) 21/89 (24%) patients had good response (51-75% regression) 24/89 (27%) patients had fair response (26-50% regression) 0/89 (0%) patients had poor response (0-25% regression)	(4), slightly elevated ALT and AST (5)	

	study								demonstrated color fading and softening of IHs. Rapid shrinkage and fading continued during the first month. Thereafter, a slower rate of involution was observed, with the majority of IHs becoming pale and nearly flat within 6 -12 mos. Total involution occurred in 7 IHs. Superficial IHs: 90% (± 8, 70- 100%) decrease in volume Combined IHs: 79% (± 11, 54- 94%) decrease in volume		patients had mild regrowth, which regressed spontaneously by 4 wks
									13/14 ulcerated IHs healed within the first month.		
Kagami etal.	Prospective study	2010-2012	9 mos*	15	3 mos	Various	2	3	Compared to the laser and/or cryosurgery control group, propranolol treatment demonstrated significantly shorter time from initiation of therapy to growth arrest [median 41 (range, 11–147) vs. 14 (7–53) days], start of shrinking [93 (11–151) vs. 21 (7–95) days], and start of color regression [53 (11–98) vs. 21 (7–72) days].	None	None during the 56– 287 day post- treatment follow-up
Holmes et al.	Prospective clinical study	First publish ed in 2010	3 mos*	31	4 mos	Various	3	3	Proliferation quickly ceased in 100% of IHs, and significant regression occurred in 87%. Palpable softening, color change, and proliferation cessation occurred within 48 hrs in 74% (23/31) of patients. Proliferation ceased by 2 wks in the remaining 26% (8/31) of patients. Regression was noted within 2 wks in 55% (17/31) of patients, within 4 wks in 16% (5/31) of patients, and within 10 wks in 16% (5/31) of patients. 13% (4/31) of IHs remained stable in size.	Transient asymptomatic hypotension during a propranolol loading dose that resolved before the subsequent dose (1), gastroesophageal reflux (1), restless at night (1), bronchiolitis (1)	24% (6/25); retreatment with propranolol was effective in all patients
									without evidence of regression. 3 of the 4 patients		
									with stable IH were >9 mos old. Ulceration epithelialization was seen in 7/8 patients within 3 wks of treatment. The other ulcerated IH was only treated for 1 wk.		
Corapcio ğlu et al.	Prospective clinical study	Publish ed 2011	6 mos*	12	8 mos	Various	2	3	with stable IH were 59 mos old. Ulceration epithelialization was seen in 7/8 patients within 3 wks of treatment. The other ulcerated IH was only treated for 1 wk. At the 2 <sup>nd</sup> month of propranolol therapy, the regression rate of the mean dimension of the IH was 38 ± 15% (range 15-50%, median 45%). Over 9 months, the regression rate of the mean dimension of the IH was 55 ± 31% (range 20-80%, median 50%).	Transient bradycardia which improved spontaneously (1)	N/A
Corapcio ğlu et al. Talaat et al.	Prospective clinical study Prospective clinical study	Publish ed 2011 Publish ed 2012	6 mos* 7 mos*	12 50 infants; 80 IHs 68	8 mos	Various Various	2	3	with stable IH were 59 mos old. Ulceration epithelialization was seen in 7/8 patients within 3 wks of treatment. The other ulcerated IH was only treated for 1 wk. At the 2 <sup>nd</sup> month of propranolol therapy, the regression rate of the mean dimension of the IH was 38 ± 15% (range 15-50%, median 45%). Over 9 months, the regression rate of the mean dimension of the IH was 55 ± 31% (range 20-80%, median 50%). Size regression: Excellent: 60 (75%) Good: 15 (19%) Fair: 5 (6%) Poor: 0 (0%) No response: 0 (0%) Color clearance: Before treatment: 153 ± 22 After treatment: 42 ± 13 Sonographic assessment: Thickness (mm) Before treatment: 9 ± 9 After treatment: 0.6 After treatment: 0.6 After treatment: 0.8 Color changes, softening and size regression occurred, with IHs becoming nearly flat by the end of treatment.	Transient bradycardia which improved spontaneously (1) Ulceration and scarring (1 IH); residual and/or recoloration (5 IHs); epidermal atrophy (2 IHs); telangiectasia (5 IHs); residual fibrofatty tissue (10 IHs)	N/A 2.5% (2/80) regrowth

									who received oral	with propranolol the	
Saint- Jean et al.	Multicenter, retrospectiv e, observation al study	2008- 2009	6 mos*	33	5 mos	Ulcerated	2-3	2 or 3	The average time for complete ulceration healing was 5.7 weeks (range, 5 days- 8 months) in all propranolol- treated patients. Ulceration healing required ≥12 weeks in 3 patients. Excluding these 3 outliers, the average time for complete ulceration healing was 4.3 weeks. Head and neck ulcerated IHs healed significantly faster than those located in other areas (4 vs. 7.6 weeks, respectively). Complete pain control was achieved in 14.5 days (range, 1-60 days).	Nightmares (5), esophageal reflux (1), cool hands and feet (1)	4/29 (14%) had recurrence of ulceration; reintroduction of propranolol led to complete healing
Hermans et al.	Case series with matched historical controls	2008-2010	9 mos*	20 pts; 78 IHs	4 mos	Ulcerated	2-2.5	3	The average ulceration duration was significantly shorter for the propranolol group (9 wks) compared with the control group (22 wks). A shorter time for complete ulceration healing was noted in patients starting propranolol at a younger age. 7/10 (70%) patients who started propranolol at >3.5 mos of age had an ulceration that lasted >8.7 weeks compared with only 2/10 (20%) of patients who began treatment at an earlier age. In all patients, reduced redness and tenseness occurred within the first 3 days and continued throughout treatment. In most patients, pain decreased within a few days of starting propranolol.	Drowsiness/tirednes s (6), restless sleeping (2), cold extremities (6), poor feeding (2), gastrointestinal complaints (diarrhea, vomiting) (1)	4/19 (21%) had partial regrowth and slightly increased redness; no recurrence of ulceration
Buckmill er et al.	Retrospecti ve single	2008- 2009	Treated until 12	32	7 mos	Various	2	3	97% (31/32) improved with propranolol.	Somnolence (6), gastroesophageal	20% (1/5) that had completed therapy
	institution case series		mos old, unless in the involutio nal phase (treated at least 6 mos and until benefit ceases)						16/32 (50%) excellent responders: no additional therapy needed. Four of these patients achieved complete resolution without signs of residual disease. 15/32 (47%) partial responders: decreased size and growth but had adjuvant therapy before or after propranolol. 1/32 (3%) non-responder: persistent growth.	reflux (2), allergic rash (1), respiratory syncytial virus exacerbation (1)	
Manunza et al.	institution case series	2008- 2009	mos old, unless in the involutio nal phase (treated at least 6 mos and until benefit ceases) 8 mos*	30	6 mos	Head and neck	2	3	16/32 (50%) excellent responders: no additional therapy needed. Four of these patients achieved complete resolution without signs of residual disease. 15/32 (47%) partial responders: decreased size and growth but had adjuvant therapy before or after propranolol. 1/32 (3%) non-responder: persistent growth. Softening, color fading, and growth cessation occurred in all IHs. 26/30 patients responded within 1 wk, and the other 4/30 responded within 1 mo. All IHs showed continued improvement thereafter. There was rapid healing of small superficial ulcers, but limited response of larger deeper ulcers. In 2 patients, ulceration worsened.	reflux (2), allergic rash (1), respiratory syncytial virus exacerbation (1) Asymptomatic isolated systolic blood pressure < 70 mmHg that normalized later that day (3)	N/A
Manunza et al. Fuchsma nn et al.	Institution case series Case series Case series Multi- institutional retrospectiv e study Multicenter	2008- 2009 2008- 2009	mos old, unless in the involutio nal phase (treated benefit ceases) 8 mos* 9 mos*	30	6 mos 6 mos for early treatme nt (33 pts); 29 mos for late nt (6 pts)	Head and neck	2-3	3	16/32 (50%) excellent responders: no additional therapy needed. Four of these patients achieved complete resolution without signs of residual disease. 15/32 (47%) partial responders: decreased size and growth but had adjuvant therapy before or after propranolol. 1/32 (3%) non-responder: persistent growth. Softening, color fading, and growth cessation occurred in all IHs. 26/30 patients responded within 1 wk, and the other 4/30 responded within 1 mo. All IHs showed continued improvement thereafter. There was rapid healing of small superficial ulcers, but limited response of larger deeper ulcers. In 2 patients, ulceration worsened. 37/39 IHs treated with propranoloh had lightening of color and reduction in size within 2 weeks. Softening and healing of ulcerations also occurred within 2 weeks. In the 16 patients who had ultrasound exams, results showed decreased hemangioma thickness and vascular activity. 2/39 hemangiomas (subglottic and nasal tip) had no response on partial response. In both of these cases, propranolol treatment was delayed and given after other treatment failures.	reflux (2), allergic rash (1), respiratory syncytial virus exacerbation (1) Asymptomatic isolated systolic blood pressure < 70 mmHg that normalized later that day (3) Trouble sleeping (5), mild diarrhea (2) Agitated sleen (10)	N/A 4/30 mild recoloration 6/30 regrowth; propranolol was effective with reinitiation.

	series								44% at 8 wks		
									52% at 12 wks		
									56% at 16 wks		
									61% at 20 wks		
									65% at 24 wks		
									65% at 28 wks		
									68% at 32 wks		
									Number of IHs with ≥50%		
									reduction in severity:		
									8/71 (11%) IHs at 4 weeks		
									24/71 (34%) IHs at 8 weeks		
									42/71 (59%) IHs at 16 weeks		
Zvulunov	Multicenter	2009	4 mos*	42	28 mos	Post-	2*	N/A	In all patients, the rate of	Sleep disturbance	N/A
etal.	retrospectiv					proliferativ		· ·	involution significantly	(2), somnolence (1),	
	e case					e phase;			increased with propranolol,	transient dyspnea (1)	
	series					predomina			compared with the rate of		
						ntly mixed			involution during active		
						type			nonintervention before		
									treatment.		
									VAS reduction rate before		
									treatment was 0.4/month		
									compared to the accelerated		
									rate of 0.9/month during		
									propranolol treatment.		
									Mean VAS score of 6.8 before		
									treatment was reduced to 2.6		
									during treatment.		

\* = mean

VAS (Visual Analogue Scale)

Reported adverse events during oral propranolol therapy included asymptomatic hypoglycemia, asymptomatic decreases in blood pressure and heart rate, bronchospasm, wheezing, transient dyspnea, stridor, sleep disturbance, insomnia, somnolence, cool extremities, sweating, gastroesophageal reflux, gastrointestinal complaints (nausea, vomiting, diarrhea), slightly elevated ALT and AST, allergic rash, increased incidence of upper respiratory infections, bronchiolitis, viral gastroenteritis, streptococcal infection, dehydration, and dental caries. Four of the twenty-two studies reported no adverse events with propranolol treatment.

#### B. Oral atenolol

Only two studies, retrievable in PubMed, have been published describing the efficacy of oral atenolol in the treatment of IH (Table 2). Both studies compared atenolol to propranolol. In a randomized, double-blinded control trial, Ábarzúa-Araya et al. studied 13 patients with IH treated with atenolol for 6 months compared to 10 patients treated with oral propranolol for 6 months. The average age of patients at treatment initiation was 5 months in both arms [8]. In a prospective cohort study by de Graaf et al., 30 infants with IH treated with atenolol were compared with a historical propranolol-treated control group. The average duration of atenolol treatment was 12 months, and the average age at the time of atenolol initiation was 6 months. Of note, atenolol-treated patients were significantly younger than propranolol-treated patients [9]. Both studies report a daily dosing regimen; however, Ábarzúa-Araya et al. used 1 mg/kg/day while de Graaf et al. ranged from 1-3 mg/kg/day, with an overall average of 1.2 mg/kg/day [8, 9].

With regards to response rates, Ábarzúa-Araya et al. showed a 54% complete response compared to 60% of the patients on oral propranolol. A complete response included residual telangiectasia and redundant tissue [8]. de Graaf et al. reported no significant difference in the quantitative improvement values for the two treatment groups. They reported a 90% response rate of clinical involution for atenolol-treated patients at 2 weeks compared to a 100% response rate for propranolol-treated patients [9]. Ábarzúa-Araya et al. reported 2 patients with rebound growth after discontinuation of atenolol that responded to re-treatment [8]. de Graaf et al. did not comment on recurrence or rebound.

Only de Graaf et al. commented on the use of atenolol for ulcerated IH. Of these 8 patients, only 2 showed an inadequate response to oral atenolol at 2 weeks. One of these patients had previously failed oral propranolol.

### Table 2. Oral atenolol

Study	Study design	Year	Duration	# of	Age*	IH	Dose	Divided	Outcome/Efficacy	Adverse	Rebound/
			of	patients		location	(mg/kg/d)	daily		events	Regrowth
			therapy	treated		& type		dose			
Ábarzúa-	Double-	2012-	6 mos	13	5	Various	1	1	54% complete response	None	15% (2/13);
Araya et	blinded	2013			mos				(complete resolution;		both
al.	randomized								residual telangiectasia		responded to
	controlled								and redundant tissue		reintroduction
	trial								were considered		of atenolol
									complete response);		
									46% partial response		
									(any improvement in		
									size, color, or		
									consistency that did not		
									meet complete response		
									criteria)		
de Graaf	Prospective	2010-	12 mos*	30	6	Various	1*	1	90% (27/30) of patients	Diastolic BP	N/A
et al.	cohort study	2011			mos				showed clinical	below the 5th	
									involution (softening,	percentile for	
									color change, and size	age (1),	
									reduction) at 2-8 wks.	Transient	
									2/8 ulcerated IHs had	restless sleep	
									insufficient response	(8),	
									after 2 wks of	Constipation	
									treatment.	(2),	
									There was no significant	Diarrhea (2),	
									difference in VAS scores	Cold	
									or <b>ΔHAS</b> between the	extremities	
									atenolol and propranolol	(some)	
									groups.		

#### \*= mean

#### VAS (Visual Analogue Scale); HAS (Hemangioma Activity Score)

According to de Graaf et al., only 3% (1/30) of patients treated with atenolol had severe adverse effects (hypoglycemia, bronchial hyperreactivity, or hypotension), compared with 25% (7/28) of propranolol-treated patients. Mild adverse effects (restless sleep, constipation, and diarrhea) were reported in 40% (12/30) of atenolol-treated patients, compared with 50% (14/28) of propranolol-treated patients [9]. In contrast, Ábarzúa-Araya et al. reported no adverse events for patients treated with atenolol or propranolol [8].

#### C. Oral nadolol

One study, Pope et al., describing the efficacy of oral nadolol in the treatment of IH (Table 3) was found on PubMed. The study compared nadolol 2 mg/kg/day divided twice daily to propranolol 2 mg/kg/day divided three times daily in an assessor-blinded cohort study of 19 patients with head and neck IH. Treatment duration in both arms was 6 months. Using a Visual Analogue Scale (VAS), they found mean percentage IH shrinkage was  $51 \pm 18\%$  at 4 weeks,  $83 \pm 14\%$  at 12 weeks, and  $97 \pm 3\%$  at 24 weeks for nadolol-treated patients, compared to  $28 \pm 10\%$  at 4 weeks,  $56 \pm 17\%$  at 12 weeks, and  $86 \pm 15\%$  at 24 weeks for propranolol-treated patients. Compared to propranolol, nadolol had a faster and more favorable effect on IH. There was a significant difference in IH involution between the nadolol and propranolol groups at the end of treatment. Six months of oral nadolol treatment led to nearly complete involution of IH. There was no comment on rebound or regrowth in this study.

#### Table 3. Oral nadolol

Study	Study design	Year	Duration of therapy	# of patients treated	Age*	IH location & type	Dose (mg/kg/d)	Divided daily dose	Outcome/Efficacy	Adverse events	Rebound/ Regrowth
Ábarzúa- Araya et al.	Double- blinded randomized controlled trial	2012-2013	6 mos	13	5 mos	Various	1	1	54% complete response (complete resolution; residual telangiectasia and redundant tissue were considered complete response); 46% partial response (any improvement in size, color, or consistency that did not meet complete response critacia	None	15% (2/13); both responded to reintroduction of atenolol
de Graaf et al.	Prospective cohort study	2010-2011	12 mos*	30	6 mos	Various	1*	1	90% (27/30) of patients showed clinical involution (softening, color change, and size reduction) at 2-8 wks. 2/8 ulcerated IHs had insufficient response after 2 wks of treatment. There was no significant difference in VAS scores or AHAS between the atenolol and propranolol groups.	Diastolic BP below the 5th percentile for age (1), Transient restless sleep (8), Constipation (2), Diarrhea (2), Cold extremities (some)	N/A

\*= mean

VAS (Visual Analogue Scale); HAS (Hemangioma Activity Score)

Reported adverse events during nadolol treatment included cold extremities, gastrointestinal symptoms, sleep disturbance, and cold-induced wheezing. Additionally, asymptomatic decrease in heart rate from a mean of  $139 \pm 14$  beats per minute (bpm) to  $115 \pm 11$  bpm was recorded [7]. Adverse events of propranolol treatment and rebound growth were not included in the study.

### D. Topical timolol

Three studies describing the efficacy of topical timolol in the treatment of IH (Table 4) were retrieved from PubMed. All studies report BID application; however, timolol concentration differed (0.1, 0.25, or 0.5%). Treatment duration ranged from 2-6 months, and average age at treatment initiation was 2-8 months.

According to Chan et al., there was a marginally significant difference in IH size between timolol and placebo groups at 12 and 16 weeks, with smaller IH in the timolol group. At 8, 20, and 24 weeks, the timolol-treated patients had significantly more IH with  $\geq$  5% volume reduction. Additionally, the timolol group had significantly more photos scoring 0 (no redness) and fewer photos scoring 2 (completely red) [10]. Results from Chakkittakandiyil et al. showed improvement in 99% (72/73) of patients, with a mean VAS improvement of 45 ± 30%. The only patient who did not improve was a 4-month-old male with a mixed IH that increased in size during 2 weeks of treatment with timolol 0.5% solution [11]. Chambers et al. found IH color improved in all timolol-treated patients, and IH thickness decreased in 12/13 patients. Superficial (*n* = 5; 100% good response) and mixed (*n* = 7; 43% good response, 57% moderate response) IH decreased in size; the one deep IH increased in size (poor response) despite topical timolol treatment [12]. Overall, Chan et al. found topical timolol was more effective for IH with a mean diameter <11.3 mm [10], and Chakkittakandiyil et al. reported better response in superficial IH, with 0.5% concentration, and with treatment duration longer than 3 months [11].

### **TABLE 4: Topical Timolol**

Study	Study design	Year	Duration	# of	Age*	IH location	Dose	Freque	Outcome/Efficacy	Adverse	Rebound/
			of	patients		& type		ncy		events	Regrowth
			therapy	treated						(#patients)	
Chan et al.	Double-	2011-	6 mos	15	2 mos	Various	1 drop of	BID	Comparing timolol and placebo	None	Post-trial
	blinded,	2012				locations	0.5% gel		groups, there was a marginally		follow-up
	randomized								significant difference in IH size at		ofmost
	placebo-					Superficial			12 and 16 wks (with smaller IHs in		patients
	controlled,								timolol-treated patients) and a		showed no
	parallel-group								significant difference in †blinded		significant
	trial								photo score distribution at 24 wks.		rebound
Chakkittak	Multicenter	First	3 mos*	73	8 mos	Mostly	62/73	BID	72/73 (99%) patients improved;	Sleep	None at
andiyil et	retrospective	publis				head and	treated		mean VAS improvement was	disturbance	3–6 mos
al.	cohort study	hed in				neck	with 0.5%		45 ± 30% at the last follow-up	(1)	follow-up
		2011					gel-forming		appointment.		
						Mostly	solution				
						superficial					
							11/73				
							treated				
							with 0.1%				
							gel-forming				
		0007		10	-		solution		<b>T</b>		
Chambers	retrospective,	2007-	2 mos	13	5 mos	Non-vision-	2 drops of	BID	Timolol group	None	1/13;
et al.	consecutive,	2011				threatening	0.25% gei		8 (62%): good response**		no
	non-					periocular			4 (31%): moderate response		recurrence
	randomized,					IHS			1 (8%): poor response		atter re-
	comparative					Verterre			Observed group		initiation of
	single-masked					various			0 (0%): good response		for an
	conort study					types			1 (10%): moderate response		additional
									9 (90%): noor response		6 mos
									s (sow), poor response		o mos.
									Timolol-treated superficial $(n = 5)$		
									100% good response) and mixed		
									(n = 7: 43%  good, 57%  moderate)		
									response) IHs decreased in size: the		
									one deep IH increased in size (poor		
									response) despite topical timolol		
									treatment.		

\*= mean

+Blinded photo score = one blinded investigator scored clinical photographs based on IH redness (0 = no redness, 1 = ~50% red, and 2 = completely red).

VAS (Visual Analogue Scale) is a 100-mm scale (-100 = doubling in the size and extent of the IH, 0 = no change, and +100 = complete shrinkage). 5 mm is equivalent to a 10% change.

\*\*Response to therapy was subdivided into good (>50% decrease in size), moderate (0–50% decrease in size), and poor (increased in size or led to visually significant ptosis or astigmatism).

Rebound growth was observed in only one patient: a 5-month-old infant with a mixed IH that almost completely resolved during a 2 month course of topical timolol but increased in size within 2 weeks of stopping treatment. Regression occurred with reintroduction of timolol, and rebound growth did not recur after treatment cessation at 1 year of age [12]. Sleep disturbance in one patient was the only reported adverse event from the 101 timolol-treated patients in the reviewed studies [11].

## Conclusions

Beta blockers are currently the standard of care for IH. Oral propranolol has been the focus of most research and studies in treatment of IH. In December 2011, a multidisciplinary panel of experts established consensus recommendations (Figure 1) for propranolol pretreatment workup, initiation, formulation, target dose, frequency, and monitoring. According to these guidelines, pretreatment ECG should be obtained if heart rate is below normal for age, if the patient has a history of arrhythmia or current arrhythmia, if there is a family history of congenital heart conditions or arrhythmias, or if there is a maternal history of connective tissue disease.

The recommended formulation is 20mg/5mL preparation, and the recommended target dose is 1-3 mg/kg/day, with the majority of panel experts encouraging 2 mg/kg/day, divided into three daily doses [32]. Propranolol hydrochloride oral solution (Hemangeol®) is now FDA-approved for the treatment of proliferating IH with a concentration of 4.28 mg/ml and a recommended dose of 3.4 mg/kg/day divided into twice a day dosing [33]. A low starting dose is encouraged because most episodes of bradycardia and hypotension occur during initiation of treatment or dose escalation. Heart rate and blood pressure should be measured at baseline and 1 and 2 hours after the first propranolol dose and after dose escalations > 0.5 mg/kg/day. Also, a minimum of one set of vital signs should be measured when the patient reaches target dose. If heart rate or blood pressure

is abnormal for the patient's age, continue monitoring until they are within normal limits. Inpatient monitoring for initiation of oral propranolol is recommended for infants  $\leq 8$  weeks corrected gestational age, infants with poor social support, infants with cardiovascular or respiratory comorbidities, and infants who require maintenance of blood glucose. Otherwise, outpatient initiation of propranolol is acceptable [32].

Propranolol T	reatment Consensus Recommendations
Pretreatment ECG if	HR is below normal for age < 1 month old: < 70 bpm 1-12 months old: < 80 bpm >12 months old: < 70 bpm
	History of arrhythmia or current arrhythmia Family history of congenital heart conditions or arrhythmias
	Maternal history of connective tissue disease
Inpatient initiation if	$\leq$ 8 weeks corrected gestational age
	Poor social support
	Cardiovascular or respiratory comorbidities
	Require maintenance of blood glucose
Formulation	20mg/5mL preparation
Target dose	1-3 mg/kg/d (majority recommend 2 mg/kg/d)
Frequency	TID
HR and BP monitoring at	Baseline
	1 and 2 hours after the first propranolol dose
	After dose escalations > 0.5 mg/kg/d
	Target dose

Figure 1. Propranolol treatment consensus recommendations

More recently, investigations of the efficacy and safety of other beta blockers have been conducted. Data from Ábarzúa-Araya et al. and de Graaf et al. show similar efficacy of propranolol and atenolol in treatment of IH, with atenolol having less side effects. Furthermore, since atenolol selectively antagonizes  $\beta$  1-receptors and spares  $\beta$  2-receptors, it is not contraindicated in patients with asthma or bronchial hyper-reactivity. Another advantage of atenolol is once daily administration which may improve compliance [8, 9]. More studies are recommended to strengthen the evidence of atenolol use in IH.

According to results from the cohort study by Pope et al., nadolol was faster and more effective than propranolol for inducing IH involution. In patients with proliferative IH, nadolol had a significantly better outcome when compared to propranolol. The longer half-life of nadolol allows twice daily dosing and may increase adherence [34]. More studies of nadolol efficacy in patients with IH are needed. To our knowledge, there are no randomized controlled trials of nadolol for treatment of IH.

Hydrophilic atenolol and nadolol cannot cross the blood brain barrier, theoretically reducing CNS adverse events, such as sleep disturbance, nightmares, and potential long-term memory loss. Of note, eight patients treated with atenolol had "transient restless sleep" [9], and one patient receiving nadolol suffered from "sleeping disturbance," [34] without further details provided.

Lastly, topical timolol is a good alternative to oral propranolol for smaller, more superficial IH [10, 11, 12]. Based on our review, topical timolol may have a slower onset of action compared to oral propranolol. In addition, topical timolol may be used as an

adjunct to shorten duration of oral therapy and to prevent rebound growth. Topical therapy may be beneficial for patients who have contraindications to systemic beta blockers or parents who are worried about the adverse effects of systemic therapy.

In conclusion, the superior safety and efficacy of propranolol over previously used corticosteroids is widely accepted. Currently, oral propranolol is first-line therapy for complicated IH. However, with the emerging use of other beta blockers for IH, we may see a shift in treatment recommendations in the coming years as more studies are published and the long term effects of betablocker use in infants continues to be evaluated.

# References

- 1. Kilcline C, Frieden IJ. Infantile hemangiomas: How common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25(2):168-173. [PMID:18429772]
- Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the united states: Correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr. 2012;161(2):240-245. [PMID:22497908]
- 3. Püttgen KB. Diagnosis and management of infantile hemangiomas. Pediatr Clin North Am. 2014;61(2):383-402. [PMID:24636652]
- 4. Dalby TK, Lester-Smith D. Propranolol for the treatment of infantile haemangioma. J Paediatr Child Health. 2013;49(2):148-151. [PMID:23418706]
- 5. Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and infantile hemangiomas four years later: A systematic review. Pediatr Dermatol. 2013;30(2):182-191. [PMID:23405852]
- 6. Léauté-Labrèze C, de lR, Hubiche T, Boralevi F, Thambo J, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-2651. [PMID:18550886]
- Pope E, Chakkittakandiyil A, Lara-Corrales I, Maki E, Weinstein M. Expanding the therapeutic repertoire of infantile haemangiomas: Cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol. 2013;168(1):222-224. [PMID:22762503]
- Abarzúa-Araya Á, Navarrete-Dechent CP, Heusser F, Retamal J, Zegpi-Trueba MS. Atenolol versus propranolol for the treatment of infantile hemangiomas: A randomized controlled study. J Am Acad Dermatol. 2014;70(6):1045-1049. [PMID:24656727]
- de Graaf M, Raphael MF, Breugem CC, et al. Treatment of infantile haemangiomas with atenolol: Comparison with a historical propranolol group. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2013;66(12):1732-1740. [PMID:24011909]
- 10. Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-weekolds. Pediatrics. 2013;131(6):e1739-e1747. [PMID:23650294]
- 11. Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: A retrospective, multicenter, cohort study. Pediatr Dermatol. 2012;29(1):28-31. [PMID:22150436]
- 12. Chambers CB, Katowitz WR, Katowitz JA, Binenbaum G. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas. Ophthal Plast Reconstr Surg. 2012;28(2):103-106. [PMID:22410658]
- 13. Leaute-Labreze C, Dumas de la Roque E, Nacka F, et al. Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age. Br J Dermatol. 2013;169(1):181-183. [PMID:23301692]
- 14. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128(2):e259-66. [PMID:21788220]
- 15. Bauman NM, McCarter RJ, Guzzetta PC, et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: A randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2014;140(4):323-330. [PMID:24526257]
- 16. Malik MA, Menon P, Rao KL, Samujh R. Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study. J Pediatr Surg. 2013;48(12):2453-2459. [PMID:24314186]
- 17. Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: Follow-up report. Pediatrics. 2009;124(3):e423-31. [PMID:19706583]
- Vercellino N, Romanini MV, Pelegrini M, Rimini A, Occella C, Dalmonte P. The use of propranolol for complicated infantile hemangiomas. Int J Dermatol. 2013;52(9):1140-1146. [PMID:23829783]
- Sondhi V, Patnaik SK. Propranolol for infantile hemangioma (PINCH): An open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol. J Pediatr Hematol Oncol. 2013;35(7):493-499. [PMID:23929318]
- 20. Ma X, Zhao T, Xiao Y, et al. Preliminary experience on treatment of infantile hemangioma with low-dose propranolol in china. Eur J Pediatr. 2013;172(5):653-659. [PMID:23340697]
- 21. Celik A, Tiryaki S, Musayev A, Kismali E, Levent E, Ergun O. Propranolol as the first-line therapy for infantile hemangiomas: Preliminary results of two centers. J Drugs Dermatol. 2012;11(7):808-811. [PMID:22777220]

- 22. Kagami S, Kuwano Y, Shibata S, et al. Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas. Eur J Pediatr. 2013;172(11):1521-1526. [PMID:23812512]
- 23. Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg. 2011;64(4):445-451. [PMID:20797926]
- 24. Corapcioglu F, Buyukkapu-Bay S, Binnetoglu K, Babaoglu A, Anik Y, Tugay M. Preliminary results of propranolol treatment for patients with infantile hemangioma. Turk J Pediatr. 2011;53(2):137-141. [PMID:21853649]
- 25. Talaat AA, Elbasiouny MS, Elgendy DS, Elwakil TF. Propranolol treatment of infantile hemangioma: Clinical and radiologic evaluations. J Pediatr Surg. 2012;47(4):707-714. [PMID:22498385]
- 26. Price CJ, Lattouf C, Baum B, et al. Propranolol vs corticosteroids for infantile hemangiomas: A multicenter retrospective analysis. Arch Dermatol. 2011;147(12):1371-1376. [PMID:21844428]
- 27. Saint-Jean M, Leaute-Labreze C, Mazereeuw-Hautier J, et al. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol. 2011;64(5):827-832. [PMID:21353332]
- 28. Hermans DJJ, van Beynum IM, Schultze Kool LJ, van de Kerkhof, Peter Cornelius Maria, Wijnen MHWA, van der Vleuten, Catharina Joanna Maria. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: A study of 20 cases with matched historical controls. J Am Acad Dermatol. 2011;64(5):833-838. [PMID:21353329]
- 29. Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT. Propranolol for infantile hemangiomas: Early experience at a tertiary vascular anomalies center. Laryngoscope. 2010;120(4):676-681. [PMID:20112413]
- Manunza F, Syed S, Laguda B, et al. Propranolol for complicated infantile haemangiomas: A case series of 30 infants. Br J Dermatol. 2010;162(2):466-468. [PMID:20055816]
- 31. Fuchsmann C, Quintal MC, Giguere C, et al. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg. 2011;137(5):471-478. [PMID:21576558]
- 32. Bagazgoitia L, Torrelo A, Gutierrez JC, et al. Propranolol for infantile hemangiomas. Pediatr Dermatol. 2011;28(2):108-114. [PMID:21385205]
- 33. Zvulunov A, McCuaig C, Frieden IJ, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: A multicenter retrospective study. Pediatr Dermatol. 2011;28(2):94-98. [PMID:21362031]
- 34. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference. Pediatrics. 2013;131(1):128-140. [PMID:23266923]
- 35. Oral propranolol (hemangeol) for infantile hemangioma. The Medical Letter on Drugs and Therapeutics. 2014;56(1447):61-62. [PMID:25046418]
- 36. Pope E, Chakkittakandiyil A, Lara-Corrales I, Maki E, Weinstein M. Expanding the therapeutic repertoire of infantile haemangiomas: Cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol. 2013;168(1):222-224. [PMID:22762503]